

DAFTAR PUSTAKA

- 1 Akib A, Soepriadi M, Setiabudiawan B. Lupus Eritematosus Sistemik. In: *Buku Ajar ALergi-Imunologi Anak*. Balai Penerbit IDAI: Jakarta, 2008, pp 345–372.
- 2 Cervera R, Espinosa G. Systemic Lupus Erythematosus : pathogenesis , clinical manifestations and diagnosis. *Eular On-line Course Rheum. Dis.* 2007; : 1–31.
- 3 Alatas H. Nefritis lupus pada anak. In: Noer M, Soemyarso N, Subandiyah K, Prasetyo R, Alatas H, Tambunan T (eds). *Kompendium Nefrologi Anak*. Ikatan Dokter Anak Indonesia: Jakarta, 2011, pp 118–23.
- 4 Pusdatin Kemenkes. *Situasi Lupus di Indonesia*. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia, 2017. www.pusdatin.kemkes.go.id.
- 5 Sinha R, Raut S. Pediatric lupus nephritis: Management update. *World J Nephrol* 2014; **3**: 16.
- 6 Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. *Nat Rev Rheumatol* 2010; **6**: 538–46.
- 7 Jakes RW, Bae S-C, Louthrenoo W, Mok C, Navarra S V, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. *Arthritis Care Res (Hoboken)* 2012; **64**: 159–68.
- 8 Kasjmir I., Handoko K, Wijaya L., Hamijoyo L, Albar Z, Kalim H *et al.* *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*. Rekomendasi Perhimpunan Reumatologi Indonesia: Jakarta, 2011.
- 9 KDIGO Clinical Practice Guideline for Glomerulonephritis. *Int Soc Nephrol* 2012; **2**: 221–51.
- 10 Hahn BH, McMahon M, Wilkinson A, Wallace WD, Daikh DI, FitzGerald J *et al.* American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis. *Arthritis Care Res* 2013; **64**: 797–808.
- 11 Bertias G, Cervera R, Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. *Eular On-line Course Rheum Dis* 2012; : 476–505.
- 12 Silva CA. Childhood-onset systemic lupus erythematosus: early disease manifestations that the paediatrician must know. *Expert Rev Clin Immunol* 2016; **12**: 907–10.
- 13 Weiss JE. Pediatric Systemic Lupus Erythematosus: More Than a Positive Antinuclear Antibody. *Pediatr Rev* 2012; **33**: 62–74.
- 14 Kasjmir Y, Handono K, Wijaya L, Hamijoyo L, Albar Z, Kalim H *et al.* *Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*. Perhimpunan Reumatologi Indonesia: Jakarta, 2011.
- 15 Katsicas M, Borgia E, Villarroel I, Russo R. Accuracy of Systemic Lupus International Collaborating Clinics Classification Criteria Applied to Juvenile Systemic Lupus Erythematosus Patients. In: *ACR/AHRP Annual Meeting*. 2012.

- 16 Hartman EAR, van Royen-Kerkhof A, Jacobs JWG, Welsing PMJ, Fritsch-Stork RDE. Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-an. *Autoimmun Rev* 2018; **17**: 316–22.
- 17 Saxena R, Mahajan T, Mohan C. Lupus nephritis : current update. *Arthritis Res Ther* 2011; **13**: 240.
- 18 Spittal GW, Glasgow MBC, Uk M, Sa F, Paed M, Man DHI V *et al.* A clinical update on paediatric lupus. 2015; **105**.
- 19 Thakral A, Klein-Gitelman MS. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. *Rheumatol Ther* 2016; **3**: 209-19.
- 20 Gulay D. An Update on Treatment and Outcome of Lupus Nephritis in Children. *Ann Paediatr Rheum* 2013; **2**: 99–106.
- 21 Arıcı ZS, Batu ED, Ozen S. Reviewing the Recommendations for Lupus in Children. *Curr Rheumatol Rep* 2015; **17**.
- 22 Gibson KL, Gipson DS, Massengill SA, Dooley MA, Primack WA, Ferris MA *et al.* Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: Focus on children, adolescents, and young adults. *Clin J Am Soc Nephrol* 2009; **4**: 1962–7.
- 23 Sng A, Lau P, Liu D, Yap H. Management of Lupus Nephritis. In: Yap H, Liu D, Tay W (eds). *Pediatric Nephrology On-The-Go*. Children’s Kidney Center: Singapore, 2012, pp 136–53.
- 24 Farkhati MY, Hapsara S, Satria CD. Antibodi Anti DS-DNA Sebagai Faktor Prognosis Mortalitas pada Lupus Eritematosus Sistemik. *Sari Pediatr* 2012; **14**: 2–8.
- 25 Teh CL, Ling GR. Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. *Lupus* 2013; **22**: 106–11.
- 26 Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. *Curr Opin Rheumatol* 2001; **13**: 345–51.
- 27 Alatas H. Nefritis Lupus. In: *Buku Ajar Nefrologi*. Ikatan Dokter Anak Indonesia: Jakarta, 2002, pp 366–80.
- 28 Hernandez-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. *Clin Exp Rheumatol* 2001; **19**: 395–401.
- 29 Facó MMM, Leone C, Campos LM a, Febrônio M V, Marques HHS, Silva C a. Risk factors associated with the death of patients hospitalized for juvenile systemic lupus erythematosus. *Brazilian J Med Biol Res* 2007; **40**: 993–1002.
- 30 Blancas-Galicia L, Guevara-Cruz M, Berrón-Pérez R, Berrón-Ruiz L, Gutiérrez-Castrellón P, Espinosa-Rosales FJ. Survival of Mexican patients with paediatric-onset systemic lupus erythematosus and abnormal electroencephalogram. *Allergol Immunopathol (Madr)* 2013; **41**: 108–13.

- 31 Luca Iaccarino, Maddalena Larosa AD. *Connective Tissue Disease*. Springer International Publishing: Cham, 2016; **1** : 199-211
- 32 Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. *Clin Exp Rheumatol* 2006; **24**: 100-04.
- 33 Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: Treating-to-target and definition of treatment goals. *Autoimmun Rev* 2014; **13**: 770–7.
- 34 Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P *et al*. Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period. *Medicine*. 2003; **82**: 299–308.
- 35 Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. 2012; : 1595–1600.
- 36 Teh CL, Phui VE, Ling GR, Ngu LS, Wan SA, Tan CHH. Causes and predictors of mortality in biopsy-proven lupus nephritis: The Sarawak experience. *Clin Kidney J* 2018; **11**: 56–61.
- 37 Fischer TR, Petri M, Magder LS. Application of new EULAR definitions of remission in SLE: Durable one-year remission is rare. *Ann Rheum Dis* 2015; **74**: 814.
- 38 Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: Durable remission is rare. *Ann Rheum Dis* 2017; **76**: 547–53.
- 39 Kakati S, Teronpi R, Barman B. Frequency, pattern and determinants of flare in systemic lupus erythematosus: A study from North East India. *Egypt Rheumatol* 2015; **37**: 55–9.
- 40 Talib S, Bhattu S, Bhattu R, Db Dahiphale D. Dengue fever triggering systemic lupus erythematosus and lupus nephritis: a case report. *Int Med Case Rep J* 2013; **6**: 71–5.
- 41 Rajadhyaksha A, Mehra S. Dengue fever evolving into systemic lupus erythematosus and lupus nephritis: A case report. *Lupus* 2012; **21**: 999–1002.
- 42 Visser K, Houssiau FA, Antonio J, Silva P. Systemic lupus erythematosus : treatment. *EULAR online course Rheumatic Dis* 2007; **18**.
- 43 Wu G, Jia X, Gao D, Zhao Z. Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center. 2014; : 947–53.
- 44 Li J, Pan Z, Liu H, Ding F, Shu Q, Li X. Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. *Medicine* 2018; **97** : 27.
- 45 Malattia C, Martini A. Paediatric-onset systemic lupus erythematosus. *Best Pract Res Clin Rheumatol* 2013; **27**: 351–62.
- 46 Descloux E, Durieu I, Cochat P, Vital-durand D, Ninet J, Fabien N *et al*. Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. *Rheumatology* 2009; **48**: 779–84.
- 47 Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. *Semin Arthritis Rheum* 2013; **43**: 352–61.



- 48 Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort. *Arthritis Rheum* 2012; **64**: 4021–28.
- 49 Ushiyama O, Ushiyama K, Koa Retinal disease in patients with systemic lupus erythematosus. *Ann Rheum* 2000; : 705–8.
- 50 Giorgi D, Pace F, Giorgi A, Bonomo L, Gabrieli CB. Retinopathy in systemic lupus erythematosus: Pathogenesis and approach to therapy. *Hum Immunol* 1999; **60**: 688–96.
- 51 Kharel R, Shah DN, Singh D. Role of lupus retinopathy in systemic lupus erythematosus. *J Ophthalmic Inflamm Infect* 2016; **6**: 4–7.
- 52 Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. *Rheumatology* 2007; **46**: 1757–62.
- 53 Steinlin MI, Blaser SI, Gilday DL, Eddy a a, Logan WJ, Laxer RM *et al.* Neurologic manifestations of pediatric systemic lupus erythematosus. *Pediatr Neurol* 1995; **13**: 191–7.
- 54 Muscal, E Brey R. Neurological Manifestations of Systemic Lupus Erythematosus in Children and Adults. *Neurol Clin* 2010; **28**: 61–73.
- 55 Yu H-H, Lee J-H, Wang L-C, Yang Y-H, Chiang B-L. Neuropsychiatric manifestations in systemic lupus erythematosus. *Lupus* 2006; **15**: 651–7.
- 56 Ryan MJ. The pathophysiology of hypertension in systemic lupus erythematosus. *Am J Physiol Regul Integr Comp Physio* 2009; **296**: 1258–67.
- 57 Taylor EB, Ryan MJ. Understanding mechanisms of hypertension in systemic lupus erythematosus. *Ther Adv Cardiovasc Dis* 2017; **11**: 20–32.
- 58 Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F *et al.* Lupus nephritis in children: Prognostic significance of clinicopathological findings. *Nephron* 2001; **87**: 118–26.
- 59 Tzavara V, Pamfil C, Boumpas DT, Bertsias GK. An update on the management of comorbid conditions in lupus nephritis. *J Clin Investig* 2013; **3**: 281–93.
- 60 Schmajuk G, Yazdany J. Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review. *Semin Arthritis Rheum* 2011; **40**: 559–75.
- 61 Visser L, Singh R, Young M, Lewis H, McKerrow N. Guideline for the prevention, screening and treatment of retinopathy of prematurity (ROP). *South African Med J* 2013; **103**: 116–25.
- 62 Petri M, Purvey S, Fang H, Magder LS. Predictor of Organ Damage in Systemic Lupus Eythematosus: the Hopkins' Lupus Cohort. *Arthritis Rheum* 2012; **64**: 4021–28.
- 63 Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C *et al.* EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. *Ann Rheum Dis* 2008; **67**: 195–205.
- 64 Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic



- lupus erythematosus. *Expert Rev Clin Immunol* 2017; **13**: 35–41.
- 65 Yong PF, D’Cruz DP. Mycophenolate mofetil in the treatment of lupus nephritis. *Biologics* 2008; **2**: 297–310.
- 66 Gulay CB, Dans LF. Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus. *Pediatr Rheumatol* 2011; **9**: 7.
- 67 Hadinegoro SR, Chairulfatah A, Latief A, Pudjiadi AH, Malisie RF, Alam A. *Konsensus Diagnosis dan Tatalaksana Sepsis pada Anak*. Ikatan Dokter Anak Indonesia: Jakarta, 2016.
- 68 Rodriguez Montero S, Martinez R, Marengo J. Hospitalisation of individuals with systemic lupus erythematosus: an analysis of 84 patients. *Ann Rheum Dis* 2011; **70**: 83–4.
- 69 Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. *Rheumatology* 2007; **46**: 895–8.
- 70 Borges MC, dos Santos F de MM, Telles RW, Lanna CCD, Correia MITD. Nutritional status and food intake in patients with systemic lupus erythematosus. *Nutrition* 2012; **28**: 1098–103.
- 71 dos Santos F de MM, Borges MC, Correia M, Telles RW, Lanna CC. Assessment of nutritional status and physical activity in systemic lupus erythematosus patients. *Brazilian J Rheumatol* 2010; **50**: 5–12.
- 72 Hersh A. Measures of health-related quality of life in pediatric systemic lupus erythematosus: Childhood Health Assessment Questionnaire (C-HAQ), Child Health Questionnaire (CHQ), Pediatric Quality of Life Inventory Generic Core Module (PedsQL-GC), Pediatric Quali. *Arthritis Care Res* 2011; **63**: 446–53.